top of page

Dementia with Lewy bodies

RewinD-LB-Logo-FINAL-300x73.png

Dementia with Lewy Bodies (DLB) affects more than 1 million people in the US. DLB is noted for memory deficits, visual hallucinations, sleep REM disorders, variable levels of attention, and/or movement disorders. Currently there is no target therapies for DLB which are FDA approved.

​

This study is called REWIND-LB and is sponsored by EIP and the National Institute of Aging.

​

Screening for this study has closed of May 9, 2024. We can no longer screen any more candidates for this study.

​

What is this study about?

DLB is characterized by progressive dementia, and fluctuating problems with memory and attention. Sleep disturbances, hallucinations, as well as tremors and problems with movement (called Parkinsonism) are also common symptoms. Managing this disease can be difficult and disruptive for both people with DLB and their caregivers. There is no currently approved medication that targets the underlying cause and process of DLB.

This study will evaluate neflamapimod to see if it can improve learning skills, problem solving skills, and memory loss in people with DLB.

​

What’s involved?

By participating in this study, you can contribute to research and development of an investigational drug candidate.

Participants will complete a screening visit to find out if they qualify for the study. Participants who pass screening and choose to enroll in the study will be assigned to take a neflamapimod capsule or a placebo capsule. Both capsules will look the same, but the placebo has no active ingredients. The assignment is made randomly like flipping a coin. The assigned treatment will be taken 3 times a day for 16 weeks (4 months). During the treatment period, participants will visit the study center for tests and exams 6 times and one additional time after the treatment period ends.

All study participants who complete the initial 16-week period of the study will be able to continue in the study and receive neflamapimod for an additional 32 weeks (8 months), regardless of whether they received neflamapimod or placebo during the first 16 weeks. The extension study will involve an additional 5 study center visits.

​

Who can participate?

An individual may be able to take part in the study if he/she meets the following qualifications:

  • Men or women who are 55 years or older

  • People who:

    • have probable dementia with Lewy bodies (DLB)

    • have a reliable caregiver who can come to study center visits and help with study procedures and evaluations

bottom of page